2. Search Result
Search Result
Results for "

T ype 2 diabetes

" in MedChemExpress (MCE) Product Catalog:

3751

Inhibitors & Agonists

23

Screening Libraries

47

Fluorescent Dye

203

Biochemical Assay Reagents

373

Peptides

14

MCE Kits

161

Inhibitory Antibodies

481

Natural
Products

513

Recombinant Proteins

171

Isotope-Labeled Compounds

103

Antibodies

47

Click Chemistry

141

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-141578
    C18:1-Ceramide

    		Endogenous Metabolite Metabolic Disease
    C18:1-Ceramide is a ceramide subspecies. C18:1-Ceramide can be used in the study of type 2 diabetes
    C18:1-Ceramide
  • HY-105063
    DiaPep277

    		HSP Metabolic Disease Inflammation/Immunology
    DiaPep277 is a 24 amino acid peptide derived from positions 437-460 in HSP60. DiaPep277 arrests the progression of β-cell destruction in NOD mice. DiaPep277 has an immune modulatory effect on diabetogenic T cells in animal models of diabetes [2].
    DiaPep277
  • HY-P99383
    Volagidemab

    REMD-477; AMG-477

    		 GCGR Metabolic Disease
    Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) [2].
    Volagidemab
  • HY-161552
    T3/BSA

    		Biochemical Assay Reagents Inflammation/Immunology
    T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    T3/BSA
  • HY-161526
    T3/KLH

    		Biochemical Assay Reagents Inflammation/Immunology
    T3/KLH is an antigen-adjuvant conjugate formed by the coupling of T3 (thyroid hormone) with keyhole limpet hemocyanin (KLH). By coupling the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    T3/KLH
  • HY-158269
    T4-BSA

    		Thyroid Hormone Receptor Endogenous Metabolite Inflammation/Immunology
    T4-BSA is a biochemical reagent that can be used as a biological material or organic compound for life science related research .
    T4-BSA
  • HY-150751
    ODN TTAGGG
    1 Publications Verification

    ODN A151

    		 Toll-like Receptor (TLR) AIM2 Inflammation/Immunology
    ODN TTAGGG (A151), inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' [2].
    ODN TTAGGG
  • HY-106158
    T-1095

    		SGLT Metabolic Disease
    T-1095 is a selective and orally active Na +-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research .
    T-1095
  • HY-161528
    T3/OVA

    		Biochemical Assay Reagents Inflammation/Immunology
    T3/OVA is an antigen-adjuvant conjugate formed by conjugating T3 (thyroxine) with ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    T3/OVA
  • HY-P99790
    Priliximab

    CEN 000029; cM-T412

    		 Transmembrane Glycoprotein Inflammation/Immunology
    Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
    Priliximab
  • HY-150725
    ODN 1585

    		IFNAR TNF Receptor Infection Inflammation/Immunology Cancer
    ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant [2] .
    ODN 1585
  • HY-150726
    ODN 1668

    		Toll-like Receptor (TLR) Bacterial Infection Neurological Disease Inflammation/Immunology
    ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ [2] .
    ODN 1668
  • HY-150748
    ODN D-SL01

    		Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    ODN D-SL01, a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. ODN D-SL01 has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .
    ODN D-SL01
  • HY-108991
    T-0509

    (-)-T-0509

    		 Adrenergic Receptor Cardiovascular Disease
    T-0509 ((-)-T-0509) is a selective full agonist of the β1 receptor. T-0509 activates the cAMP signaling pathway through the β1 receptor and enhances myocardial contractility .
    T-0509
  • HY-121070
    AZD1092

    		Glucokinase Metabolic Disease
    AZD1092 is an orally active glucokinase (GK) activator with an EC50 value of 0.03 μM. AZD1092 can be used for the research of Type 2 Diabetes (T2D) .
    AZD1092
  • HY-113567
    GSK2324

    		FXR Metabolic Disease
    GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC50 of 120 nM. GSK2324 exhibits t1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively .
    GSK2324
  • HY-W015764
    T-1105
    1 Publications Verification

    		 Flavivirus Infection
    T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase [2].
    T-1105
  • HY-149332
    α-Glucosidase-IN-26

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-26 (Compound 7i) is an α-glucosidase inhibitor (IC50=4.63 µM). α-Glucosidase-IN-26 can be used in the study of type 2 diabetes mellitus (T2DM) .
    α-Glucosidase-IN-26
  • HY-W142313
    Dodecylethyldimethylammonium bromide (EDDAB), 98%(T)

    Dimethyldodecylethylammonium bromide, 98%(T)

    		 Biochemical Assay Reagents Others
    Dodecylethyldimethylammonium bromide (EDDAB), 98%(T) (Dimethyldodecylethylammonium bromide, 98%(T)) is a cationic surfactant .
    Dodecylethyldimethylammonium bromide (EDDAB), 98%(T)
  • HY-N8039
    Ganoderic acid T-Q

    Ganodermic acid T-Q

    		 Microtubule/Tubulin Cancer
    Ganoderic acid T-Q (Ganodermic acid T-Q) (compound 1) is a natural product that can be found in ganoderma lucidum. Ganoderic acid T-Q stimulates tubulin polymerization .
    Ganoderic acid T-Q
  • HY-150747
    ODN 6016

    		IFNAR Inflammation/Immunology
    ODN 6016 is a CpG-A oligonucleotides. ODN 6016 can induce IFN-α production, can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G [2].
    ODN 6016
  • HY-168484
    T-10430

    		Leukotriene Receptor Inflammation/Immunology
    T-10430 is a potent and orally active leukotriene B4 receptor 2 (BLT2) agonist. T-10430 has the potential for the research of psoriasis .
    T-10430
  • HY-Y1184B
    Potassium bicarbonate, 99.5%(T)

    Potassium hydrogen carbonate, 99.5%(T)

    		 Biochemical Assay Reagents Others
    Potassium bicarbonate, 99.5%(T) (Potassium hydrogen carbonate, 99.5%(T)) is a biologically active chemical .
    Potassium bicarbonate, 99.5%(T)
  • HY-161564
    T4/OVA

    		Biochemical Assay Reagents Inflammation/Immunology
    T4/OVA is a conjugate of T4 peptide (thyroxine T4) and ovalbumin. T4/OVA is a altered peptide, which can be used to stimulate OT-I CD8+ T cells .
    T4/OVA
  • HY-N6720
    T-2 Triol

    		Endogenous Metabolite Metabolic Disease
    T-2 Triol is a trichothecene mycotoxin derived by the metabolism of T-2 toxin. It is less toxic than T-2 toxin . T-2 Triol major metabolites are evaluated in broiler chickens with Half-lives (t1/2λz), Peak plasma concentrations (Cmax) and Tmax values of 9.6 mins, 563 ng/ml , 2.5 mins, respectively [2].
    T-2 Triol
  • HY-100682
    T-3256336

    		IAP Cancer
    T-3256336 is a potent and orally active cIAP1 and XIAP inhibitor with IC50s of 1.3, 200 nM, respectively. T-3256336 shows anti-tumor activity .
    T-3256336
  • HY-105349
    T-0156

    		Phosphodiesterase (PDE) Neurological Disease
    T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway .
    T-0156
  • HY-125594
    T-1095A

    		Drug Metabolite Metabolic Disease
    T-1095A is an active metabolite of T-1095 (HY-106158) (an SGLT inhibitor) .
    T-1095A
  • HY-163763
    T-10418

    		G2A (GPR132) Neurological Disease
    T-10418 is an agonist for G2 accumulation protein (G2A) (also known as G protein-coupled receptor GPR132) with an EC50 of 0.82 μM. T-10418 exhibits a sensitizing effect on mouse primary sensory neurons. T-10418 exhibits good pharmacokinetic characteristics, and no obvious toxicity (at 100 μM) in mouse models .
    T-10418
  • HY-161307
    T-518

    		HDAC Neurological Disease
    T-518 is an orally active, selective, and blood-brain barrier permeable HDAC6 inhibitor with an IC50 value of 36 nM for human HDAC6. T-581 can be used in research on tauopathy .
    T-518
  • HY-125930A
    T-2513 hydrochloride

    		Topoisomerase DNA/RNA Synthesis Cancer
    T-2513 hydrochloride is a selective topoisomerase I inhibitor. T-2513 hydrochloride binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death .
    T-2513 hydrochloride
  • HY-125930
    T-2513

    		Topoisomerase DNA/RNA Synthesis Cancer
    T-2513 is a selective topoisomerase I inhibitor. T-2513 binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death .
    T-2513
  • HY-151412
    T-271

    		Mitophagy Neurological Disease
    T-271 is a selective inducer of mitochondrial autophagy .
    T-271
  • HY-19352
    T56-LIMKi
    1 Publications Verification

    T5601640

    		 LIM Kinase (LIMK) Cancer
    T56-LIMKi is a selective inhibitor of LIMK2; inhibits the growth of Panc-1 cells with an IC50 of 35.2 μM.
    T56-LIMKi
  • HY-117938
    T-3861174

    		Aminoacyl-tRNA Synthetase Cancer
    T-3861174 is an inhibitor of prolyl-tRNA synthetase (PRS, Aminoacyl-tRNA Synthetase) without completely inhibiting its translation process. T-3861174 activates the GCN2-ATF4 pathway and induces death in multiple tumor cell lines, including SK-MEL-2. T-3861174 demonstrated significant antitumor activity in multiple xenograft models without significantly affecting body weight .
    T-3861174
  • HY-P0120
    Dulaglutide
    1 Publications Verification

    LY2189265

    		 GCGR Metabolic Disease
    Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) [2].
    Dulaglutide
  • HY-19261
    T-0632

    		Cholecystokinin Receptor Metabolic Disease
    T-0632 is a CCK A receptor antagonist that exhibits significant pharmacological properties in in vitro studies. T-0632 competitively inhibits the binding of [125I]CCK-8 to rat pancreatic CCK A receptors with a K_i value of 0.24 nM, which is significantly lower than the K_i value for guinea pig CCK B receptors. T-0632 has higher selectivity in inhibiting CCK-8-stimulated pancreatic enzyme release, with an IC_50 value of 5.0 nM, which is more advantageous than L-364,718 and loxiglumide. In rabbit gallbladder smooth muscle, the antagonistic effects of T-0632 and loxiglumide are reversible, while L-364,718 shows a persistent inhibitory effect. These results indicate that T-0632 is a highly potent, reversible and more selective CCK A receptor antagonist.
    T-0632
  • HY-120356A
    T-1101 tosylate
    1 Publications Verification

    TAI-95 tosylate

    		 NEKs Apoptosis Cancer
    T-1101 tosylate (TAI-95 tosylate) is the tosylate salt form of T-1101 (HY-120356). T-1101 tosylate is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 tosylate blocks the interaction between Hec1 and NEK2, exhibits cytotoxicity in human liver cancer cells with GI50 of 15-70 nM. T-1101 tosylate induces apoptosis in Huh-7. T-1101 tosylate exhibits antitumor efficacy in mouse models .
    T-1101 tosylate
  • HY-122635A
    T-448

    		Histone Demethylase Neurological Disease
    T-448 is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC50 of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons .
    T-448
  • HY-136498A
    T-705RMP ammonium

    		Drug Metabolite Infection
    T-705RMP (ammonium) is the ammonium form of T-705RMP. T-705RMP (ammonium)’s the inhibition of IMP dehydrogenase (IMPDH) activity is weak .
    T-705RMP ammonium
  • HY-11085
    T-226296

    		MCHR1 (GPR24) Metabolic Disease
    T-226296 is an oral active and selective melanin-concentrating hormone receptor antagonist with the IC50 values of 5.5 nM and 8.6 nM for human SLC-1 and rat SLC-1, respectively. T-226296 can be used for study of obesity and insulin resistance .
    T-226296
  • HY-136498
    T-705RMP

    		Drug Metabolite Infection
    T-705RMP, a phosphorylated metabolite of T-705, exhibits a very weak inhibitory effect on the IMP dehydrogenase (IMPDH) activities of the host cells, with an IC50 of 601 μM .
    T-705RMP
  • HY-B0959
    Chloramine-T

    		Bacterial Infection
    Chloramine-T is a titrimetric reagent, and an oxidizing agent. Chloramine-T is an oxidizing biocide [2].
    Chloramine-T
  • HY-161045
    T-1-DOCA

    		EGFR Apoptosis Cancer
    T-1-DOCA ia a EGFR inhibitor, with the IC50 of 56.94 and 269.01?nM for EGFR WT and EGFR T790M, respectively. T-1-DOCA can induces cell apoptosis of HCT-116 cells .
    T-1-DOCA
  • HY-B0724B
    Pazufloxacin

    T3761

    		 Bacterial Antibiotic Infection
    Pazufloxacin (T-3761) is a fluoroquinolone antibiotic.
    Pazufloxacin
  • HY-164143
    T638

    		Topoisomerase Cancer
    T638 is a topoisomerase II (TOP2) inhibitor. T638 inhibits TOP2A activity with a IC50 of 0.7 uM. T638 strongly inhibits cancer cell growth .
    T638
  • HY-N10375
    Kuwanon T

    		COX Others
    Kuwanon T is an isoprenylated flavonoid compound isolated from the root bark of Morus alba. Kuwanon T shows protective effects on t-BHP-induced oxidative stress with a EC50 of 30.32 μM .
    Kuwanon T
  • HY-W111144
    T-1330

    		Hedgehog Cancer
    T-1330 (Compound 45) is a Hh pathway inhibitor and reduces Gli1 expression .
    T-1330
  • HY-102045
    T-3764518

    		Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    T-3764518 is a novel and potent stearoyl coenzyme A desaturase (SCD) inhibitor with an IC50 of 4.7 nM.
    T-3764518
  • HY-P10356
    T100-Mut

    		TRP Channel Others
    T100-Mut is a cell-permeable peptide whose N-terminus is conjugated with a myristoylated group to enable T100-Mut to penetrate and localize to the inner side of the plasma membrane, thus mimicking the topology of Tmem100-3Q. T100-Mut can alleviate TRPA1-mediated pain .
    T100-Mut

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: